India spends about 1 percent of its gross domestic product (GDP) on public health, compared to 3 percent in China and 8.3 percent in the United States. Despite this low budget allotment, the contribution has been decreasing or kept stagnant in India since several years.
[adsense:336x280:8701650588]
President Trump promised to review the Food and Drug Administration could make major changes, including steps to accelerate the approval process of new prescription drugs, setting up a shock with critics who say its push for the Deregulation could put consumers at risk.
In response to a written question in Rajya Sabha, Minister of State for Health Faggan Singh Kulaste stated that a subcommittee formed to consider issues related to online drug sales presented its recommendations suggesting the creation of a national portal to monitor such sales as well as certain restrictions imposed on them.
The capitalization of export opportunities in regulated and semi-regulated markets was the way forward for the Indian pharmaceutical sector. The government's ease of driving policy should benefit several Indian drug manufacturers.
Antibiotic resistance is the result of environmental and behavioral causes. Indiscriminate antibiotic prescribing and lax enforcement laws are the main causes of antimicrobial resistance. This may be due to reckless use of antibiotics in hospitals as well as in private practice outside the easy availability of prescription drugs in the country.
Hundreds of scientists and academics from around the world are offering laboratory and office space to researchers stranded by the U.S. travel ban.
According to information provided by the Medical Council of India, there are a total of 9,88,922 allopathic doctors registered with the state medical council or MCI as of June 30, 2016.
The Union health ministry has notified the Medical Devices Rules, 2017. The rules will come into effect from January 1, 2018. This rule has been introduced for the first time in the world.
NPPA issues revised internal guidelines on discontinuation of production of scheduled formulations under paragraph 21 (2) of the DPCO, 2013.
The life sciences sector had high expectations of the budget not only from the point of view of tax incentives, but also from a regulatory point of view. Expectations were based on the Government's vision of making India one of the top three pharmaceutical markets by 2020. This year too, no specific impetus was given to the sector.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
